Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme

Feb 25 2009

• By Bridget Silverman

Related Content

Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say

Feb 23 2009

Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash

Jan 14 2009

Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Oct 01 2007

Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential

Feb 25 2009

Pfizer Unveils New San Francisco-Based Biotech Center, R&amp;D Leaders

Oct 04 2007

Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA

Nov 05 2008

Senate Biosimilars Bill Readied For Take-Off In Next Congress

Nov 25 2008

Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest

Oct 06 2008

Merck’s Ambitious Plans For Follow-On Biologics

Dec 15 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window